Document Detail

Levodopa does not change cerebral vasoreactivity in Parkinson's disease.
MedLine Citation:
PMID:  23238963     Owner:  NLM     Status:  Publisher    
The aim of this work was to study cerebral vasoreactivity to hypercapnia in Parkinson's disease (PD) before and after levodopa administration. The prospective study was conducted in 20 patients presenting with PD, using 3T blood oxygenation level-dependent (BOLD) functional MRI (fMRI) covering the whole brain. The hypercapnic stimulus was block-designed using carbogen inhalation, a gas mixture of 7% CO(2) and 93% O(2) , before (OFF) and 60 minutes after administration of a suprathreshold (120%) therapeutic L-dopa dose (ON). Ten age-matched controls were enrolled for between-group comparisons. Analyses were conducted with a random effects model and corrected for multiple comparisons. No adverse reaction to the hypercapnic stimulus was reported. However, 10 patients and 2 controls were excluded because of incomplete protocol realization, inappropriate hypercapnic stimulus, or excessive movements, leaving 10 patients and 8 controls for further analyses. The hypercapnic stimulus increased whole-brain BOLD signal of 1.48% ± 0.06% (mean ± standard error) in controls, 1.59% ± 0.05% in patients OFF, and 1.62% ± 0.09% in patients ON. Regions of interest analyses showed a signal increase in gray matter of 2.60% ± 0.16% in controls, 2.89% ± 0.21% in patients OFF, and 2.87% ± 0.12% in patients ON. No global or regional significant difference was detected, when comparing patients OFF and ON L-dopa, or between patients and controls. Contrary to Alzheimer's disease, the vasoreactivity to hypercapnia was normal in PD before and after L-dopa administration, compared to controls. This negative result is an important finding, especially for neuroscientists using fMRI to investigate motricity and cognition, discarding a significant confounding effect. © 2012 Movement Disorder Society.
Alexandre Krainik; Audrey Maillet; Vanessa Fleury; Mehmet Sahin; Irène Troprès; Laurent Lamalle; Stephane Thobois; Valerie Fraix; Marjorie Villien; Jan Warnking; Pierre Pollak; Serge Pinto; Paul Krack
Related Documents :
23859343 - Erythropoietin in friedreich ataxia.
24154023 - Predominance of allergic bronchopulmonary aspergillosis (abpa) in african americans wit...
943273 - Estimation of the resting reflex hypoxic drive to respiration in patients with diffuse ...
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2012-12-12
Journal Detail:
Title:  Movement disorders : official journal of the Movement Disorder Society     Volume:  -     ISSN:  1531-8257     ISO Abbreviation:  Mov. Disord.     Publication Date:  2012 Dec 
Date Detail:
Created Date:  2012-12-14     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8610688     Medline TA:  Mov Disord     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Copyright Information:
Copyright © 2012 Movement Disorder Society.
Department of Neuroradiology and MRI, University Hospital of Grenoble, Grenoble, France; Inserm U836, Grenoble, France; Joseph Fourier University, Grenoble Institute of Neurosciences UMR-S836, Grenoble, France.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Dietary B vitamin intake and risk of hip fracture: the Singapore Chinese Health Study.
Next Document:  Frontal and temporal contributions to understanding the iconic co-speech gestures that accompany spe...